Literature DB >> 8419072

Antiretroviral treatment reverses HIV-induced reduction in the expression of surface antigens on alveolar macrophages in AIDS patients.

D H Bray1, S B Squire, A Kawana, M A Johnson, L W Poulter.   

Abstract

MoAbs and immunoperoxidase methods were used to identify antigen-presenting and phagocytic cells and to assess expression of HLA-DR molecules on cells obtained by bronchoalveolar lavage (BAL) from 33 AIDS patients and nine normal volunteers. In 17 patients, not receiving antiretroviral therapy, the expression of HLA-DR molecules (MoAb RFDR1) as well as the percentages of cells expressing RFD1 marker for antigen-presenting cells and RFD7 marker for mature phagocytes were significantly reduced. However, in BAL obtained after commencing treatment with zidovudine (AZT) in 21 patients or with 2',3'-dideoxyinosine (DDI) in five patients, the expression of the markers studied was found to have returned to levels of expression seen in normal lavages. The changes observed were clearly associated with antiretroviral treatment and did not correlate with applications of other drugs, blood CD4 counts or presence of infectious organisms in BAL fluid. As the alterations in the expression of HLA-DR molecules and RFD1 marker on macrophages have been shown to be associated with functional capacities of these cells, the reversal of impaired expression of phenotypic markers on alveolar macrophages in AIDS patients by AZT and DDI signifies an important ability of these drugs to modify immune reactivity and emphasizes the need to monitor such functions in HIV disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8419072      PMCID: PMC1554652          DOI: 10.1111/j.1365-2249.1993.tb03346.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

1.  Changes in lung macrophages during disease.

Authors:  L W Poulter
Journal:  FEMS Microbiol Immunol       Date:  1990-12

2.  Inhaled corticosteroids can modulate the immunopathogenesis of pulmonary sarcoidosis.

Authors:  M A Spiteri; S P Newman; S W Clarke; L W Poulter
Journal:  Eur Respir J       Date:  1989-03       Impact factor: 16.671

3.  Characterization of immune inducer and suppressor macrophages from the normal human lung.

Authors:  M A Spiteri; L W Poulter
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

4.  Accessory cell function of human alveolar macrophages in antigen-induced T lymphocyte proliferation.

Authors:  M Ohtsuka; Y Yoshizawa; T Sato; H Yano; R Mukai; S Hasegawa; V L Moore
Journal:  Int Arch Allergy Appl Immunol       Date:  1989

5.  The distribution of phenotypically distinct macrophage subsets in the lungs of patients with cryptogenic fibrosing alveolitis.

Authors:  B Noble; R M Du Bois; L W Poulter
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

6.  Phenotypic changes in monocytes and alveolar macrophages in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC).

Authors:  G Roy; N Rojo; F Leyva-Cobián
Journal:  J Clin Lab Immunol       Date:  1987-07

Review 7.  Role of mononuclear phagocytes in the pathogenesis of human immunodeficiency virus infection.

Authors:  M S Meltzer; D R Skillman; P J Gomatos; D C Kalter; H E Gendelman
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

8.  Dendritic cell infection, depletion and dysfunction in HIV-infected individuals.

Authors:  S E Macatonia; R Lau; S Patterson; A J Pinching; S C Knight
Journal:  Immunology       Date:  1990-09       Impact factor: 7.397

9.  Reduced Langerhans' cell Ia antigen and ATPase activity in patients with the acquired immunodeficiency syndrome.

Authors:  D V Belsito; M R Sanchez; R L Baer; F Valentine; G J Thorbecke
Journal:  N Engl J Med       Date:  1984-05-17       Impact factor: 91.245

10.  The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.

Authors:  M A Fischl; D D Richman; N Hansen; A C Collier; J T Carey; M F Para; W D Hardy; R Dolin; W G Powderly; J D Allan
Journal:  Ann Intern Med       Date:  1990-05-15       Impact factor: 25.391

View more
  3 in total

1.  Does analysis of bronchoalveolar lavage fluid provide a tool to monitor disease progression or to predict survival in patients with HIV-1 infection?

Authors:  C Agostini; G Semenzato
Journal:  Thorax       Date:  1994-09       Impact factor: 9.139

2.  Changes to alveolar macrophage phenotype in HIV infected individuals with normal CD4 counts and no respiratory disease.

Authors:  M C Lipman; M A Johnson; D H Bray; L H Poulter
Journal:  Thorax       Date:  1995-07       Impact factor: 9.139

3.  Myeloid cells in cancer progression: unique subtypes and their roles in tumor growth, vascularity, and host immune suppression.

Authors:  Pampee P Young; Shidrokh Ardestani; Bin Li
Journal:  Cancer Microenviron       Date:  2010-04-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.